(From left to right: Dr. Jacky Lio, Chief Medical Officer of Bowtie; Mr. Fred Ngan, Co-Founder and Co-CEO of Bowtie; Professor Tony Mok; Mr. Michael Chan, Co-Founder and Co-CEO of Bowtie)
Professor Mok is currently the Chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology of the Faculty of Medicine at The Chinese University of Hong Kong. His work encompasses clinical research on oncogene driven lung cancer and the application of immunotherapy, much of his research has shifted the treatment paradigm and defined the current management of lung cancer. Professor Mok had been widely recognized by the medical field, he was also named as one of the “Giant of Cancer Care” by OncLive in 2022, a leading multimedia cancer resource platform.
“Professor Mok is the hall of fame in the medical world. His decision to join Bowtie as Health Advisor instead of other long-established insurers means a lot to our team. Moreover, it is a testament to our commitment in becoming a category-defining health insurer.” said Fred Ngan, Co-Founder and Co-CEO of Bowtie.
“The overall incidence of cancer in Hong Kong has been increasing, although medical advancement is making personalised early cancer detection and treatment possible, at the same time, it is getting more expensive. In order to save lives, the top priority of our society should be unlocking private medical services for the general public, enabling their access to cancer treatment as well as other private healthcare.” said Dr. Jacky Lio, Chief Medical Officer of Bowtie.
“We are very pleased to learn under Professor Mok’s guidance. He has devoted his entire career to improving the survival rate of cancer patients and their quality of life, which coincides with the Preventive Care concept that Bowtie has been advocating, both sides fit in easily.” supplemented by Dr. Jacky Lio.
“As a Hong Konger, I am really glad to see a local startup company shouldering the social responsibility of Hong Kong people’s health. Witnessing the two co-founders and their team focusing on the same goal, reminded me of myself when I returned to Hong Kong from Canada for scientific research. It is obvious and apparent that guiding Bowtie is the correct decision. I have always hoped that with advanced detection, more integrative therapeutic strategy and various medical support, we can provide patients with better care.” said Professor Tony Mok.
In addition to serving as the Health Advisor at Bowtie, Professor Mok is also serving as a board member in a number of well-known companies, including, AstraZeneca PLC, HUTCHMED (China) Limited, Aurora Tele-Oncology Ltd.etc.
The Bowtie Life Insurance Company Limited is an authorised life insurance company and Hong Kong’s very first virtual insurer approved under the Fast Track pilot scheme. Through the use of modern technology and medical expertise, Bowtie offers a commission-free convenient online platform for customers to quote, apply and claim for health insurance plans certified by the Health Bureau under the Voluntary Health Insurance Scheme (VHIS). Bowtie is backed by Sun Life Financial, Mitsui & Co., Ltd and supported by leading international reinsurers.
Stay up to date at www.bowtie.com.hk.
